OncoMatch/Clinical Trials/NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Is NCT06657222 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TUB-030 for advanced solid tumors.
Treatment: TUB-030 — The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Head and Neck Squamous Cell Carcinoma
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale Cancer Center · New Haven, Connecticut
- University of Miami · Miami, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- Mayo Clinic · Rochester, Minnesota
- Washington University · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify